Key facts
- Notable investors include Anhong Zhifei Investment Management, Tibet Rhodiola Pharmaceutical Holding.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nuoen Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuoen Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuoen Genomics
Researcher and developer of nucleic acid drugs intended for mRNA vaccine development. The company focuses on the research and development of nucleic acid drug delivery and nucleic acid sequence modification platform technologies to provide genetic and protein research, technical services and development of molecular diagnostic products, enabling researchers and patients with good medicinal efficacy, stable physical and chemical properties, low-toxicity and low-immunogenicity nucleic acid drug.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2011
- Website
- mirbay.com/
- Ownership
- Privately Held (backing)
Nuoen Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuoen Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuoen Genomics in its N-PORT filings yet. We sweep new filings monthly.